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Tingyi Li: Optimizing protein purification for RNA-binding recombinant fusion proteins 
(Under the direction of Juliane Nguyen) 
          There has been great interest in delivering short interfering RNA (siRNA) and 
microRNA (miRNA) for therapeutic applications. However, the delivery of small RNAs 
remains challenging due to its inefficient cellular uptake and instability under 
physiological conditions. Here, we engineered a  CXCR4-targeting RNA-protein 
nanoplex that consists of a CXCR4-targeting single-chain variable fragment (scFv) 
antibody, which is fused to an RNA-binding protamine peptide 
(RSQSRSRYYRQRQRSRRRRRRS). To obtain a functional RNA-binding protein, the 
removal of external nucleic acids is essential. This study aims to optimize the purification 
process of RNA-binding fusion proteins to free up RNA-binding domains and study if 
protein/siRNA complexes could successfully protect and deliver siRNA to silence cellular 
genes. After testing out different nucleic-acid removal methods, the high-salt-wash 
assisted immobilized metal affinity column purification method showed a great reduction 
of bound nucleic-acid contaminants. The purified fusion proteins showed a successful 
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OPTIMIZING PROTEIN PURIFICATION FOR RNA-BINDING RECOMBINANT 
FUSION PROTEINS 
Introduction 
Small RNAs such as small-interfering (siRNA) and microRNA (miRNA) are short 
(~18 to 30 nucleotides) non-coding RNA molecules that can regulate gene expression 
by post-transcriptional modification. As important regulators of physiology and 
development, they play a critical part in cellular processes such as differentiation, 
proliferation, metabolism.1.Compelling evidence has illustrated that miRNA expression 
is dysregulated in human cancer. The miRNA could be either oncogenes or tumor 
suppressors, which affect cancer hallmarks, including activating invasion or metastasis, 
inducing angiogenesis, and many other factors1. Because small RNAs do not integrate 
into the genome and can be synthesized easily, the field of small RNAs drug 
development has expanded considerably. Several small RNA-targeted therapeutics 
have been recently approved by the FDA, such as patisiran and givosiran, approved in 
2018 and 2019 respectively. The first FDA-approved siRNA drug, patisiran is approved 
for hereditary transthyretin-mediated (hATTR) amyloidosis and works by degrading the 
messenger RNA transcript for transthyretin. Clinical trials have demonstrated significant 
improvements in patients’ quality of life and consistently slowed neuropathy progression 
2. The second siRNA drug, givosiran was approved for acute intermittent porphyria by 
inhibiting hepatic delta-aminolevulinic acid synthase 1 (ALAS1) synthesis, thereby 




have not yet translated into FDA-approved candidates for medical intervention, there 
are on-going phase 1 and phase 2 clinical trials of candidate drugs. For instance, 
ENGeneIC has designed a bacterially derived minicell containing miRNA mimic, 
MesomiR-1. This miRNA mimic aims to replace miR-16, a tumor suppressor that is 
reduced in cases of cancer, including malignant pleural mesothelioma or non-small cell 
lung cancer 4. In the first human trial, the drug was reported to suppress tumor transcript 
miR-16 5. 
Moreover, some small RNAs are also under preclinical and clinical development 
for replacement therapy or vaccination 6,7. Most RNA drugs are designed to act 
intracellularly, but RNA molecules are intrinsically unstable and cannot freely cross 
cellular membranes due to their anionic charges and large molecular weight. Therefore, 
new approaches and technologies are needed to tackle these issues by not only 
protecting cargo from degradation but also helping it to cross the cellular membrane. 
Among all the existing RNA delivery vehicles, protein-based carriers are highly 
attractive because of their unique engineerability. The size, charge, binding affinity, and 
targeting moieties of proteins could be easily manipulated to optimize therapeutic 
cargos' pharmacological efficacy. For many therapeutic applications such as treatments 
against cancer, specific cellular uptake is critical to minimize side effects and to 
enhance therapeutic efficacy. As such, studies have genetically fused short RNA-
binding motifs (RBM) to targeting ligands, such as single-chain variable fragments 
(scFvs) for binding to cellular receptors. For instance, Zang et al. have developed a 
fusion protein (R3P) consisting of FGFR3-scFv-protamine, which could successfully 




8. Additionally, Jiang et al. found that their fusion protein, anti-HER2-scFv-arginine 
nonamer peptide (e23sFv-9R), showed a significant anti-cancer effect while delivering 
CXCR4 siRNA 9.  
In addition, our lab has also engineered a first-generation CXCR4-targeting 
protein/miRNA nanoplex system, which is composed of CXCR4-targeting scFvs fused 
with a short protamine peptide sequence RSRYYRQRQRSRRRRRRS for miRNA 
delivery (hereinafter referred to as CXCR4_RBM). The protamine peptide is commonly 
used for fusion to scFv for small RNA delivery 10. Because of the electrostatic interaction 
between the negatively charged RNA and positively charged protamine sequence, the 
CXCR4_RBM fusion protein and miRNA will self-assemble into nanoplexes that serve 
as protective vehicles for delivery of therapeutic miRNA (Fig. 5B). Our published results 
have shown that the CXCR4_RBM fusion proteins are able to repolarize macrophages 
to suppress tumors through the CXCR4 blockade, and the co-delivery of M1-polarizing 
miRNAs using nanoplexes enhanced the outcome 10. However, the improvement was 
not statistically significant. Previous studies published by others were lacking critical 
controls and failed to include non-specific siRNA as a comparison. Thus, the observed 
gene silencing could be partially due to toxic effects or off-target effects. We 
hypothesized that 1) the RNA-binding region may be limited or occupied due to 
unwanted binding with bacterial nucleic acids; 2) the complexation efficiency and RNA-
loading efficiency is insufficient due to the short RBM region or low charge density.  
We selected Escherichia coli (E. coli) as our biological protein factory because of 
the existence of well-established protocols, its rapid growth, and high-level protein 




RNA or DNA during overexpression. In order to isolate a functional RNA-binding 
protein, complete purification of the protein is essential; otherwise, the contaminants will 
interfere in subsequent biological assays and characterization of the protein-RNA 
complexes. We implemented several approaches to solve the contamination issue, 
including ultracentrifugation, polyethylenimeine (PEI) treatment, anion exchange 
columns, and high-salt washes. 
Materials and Methods 
Cloning of recombinant protein-coding plasmids 
We have identified an scFv sequence that specifically binds to CXCR4, and this 
protein was cloned into a pet21a vector (Novagen, Burlington, MA). This clone was then 
used as the vector for cloning the CXCR4-1P (shown in Fig.1). The pET21a was 
digested with restriction enzymes, NdeI and XhoI (NEB) 4 hours at 37 oC. The CXCR4 
insert was amplified using PCR with forward and reverse primers shown in Table.1. 
Briefly, The PCR reaction mixture contained forward and reverse primers added to a 
final concentration of 0.5 µM concentration, 10 ng of template DNA, 5 µL of 5X Q5 
reaction buffer, and 0.25 µL of Q5 polymerase (New England Biolabs [NEB], Ipswich, 
MA).  The PCR reaction was activated at 94°C for 1 minute followed by 25 cycles at 
94°C for 1 minute, 69°C for 1 minute, and 72°C for 1 minute. The PCR product was then 
purified and digested with the same restriction enzyme pair, NdeI and XhoI.  Both 
digested PCR and vectors were prepared with gel loading dye (NEB) and then loaded 
onto 0.8% agarose gel. The gel electrophoresis was performed at 120 V for 20 minutes 
using a Bio-Rad PowerPac (Hercules, CA) and the gel was imaged on the Bio-Rad 




QIAquick Gel Extraction Kit (Qiagen) as described by the manufacturer. A 1:10 vector to 
insert molar ratio ligation reaction was prepared with a T7 DNA ligase reaction kit 
(NEB). The ligation reaction was then incubated at 16 oC overnight. Total 2 ul of the 
ligation reaction was transformed into 25 ul of chemically competent cells, NEB-5α 
(NEB), through heat-shock and then plated on LB+Ampcilin agar plates for overnight 
incubation at 37 oC. On the following day, the colonies grown on the agar plates were 
selected for plasmid isolation. All the plasmid was isolated using Plasmid Mini Kit 
(Norcross, GA) following the manufacturer’s instructions. DNA concentrations were 
measured using NanoDrop 2000 (Thermofisher Scientific, Waltham, MA). The 
sequences for the clone were confirmed by the Genwiz sequencing company. For the 
cloning of CXCR4-1P, CXCR4_2P, the same procedure was performed with different 
restriction enzyme pairs shown in Figure1. 
Inclusion body isolation  
The CXCR4-scFv cloned into the pET21a vector (Novagen, Burlington, MA) was 
transformed into BL-21 (DE3) cells (Lucigen, Middleton, WT). The BL21 cells producing 
the CXCR4_scFv or CXCR4_RBM fusion proteins were initially grown overnight at 37 °C 
in LB broth with 100 μg/mL ampicillin, shaking at 250 rpm. Then, the overnight culture 
was diluted in a 1:100 ratio in a 1 L culture media bottle and incubated at 37 °C until 
reached an optical density at 600 nm (OD600) of 0.6. The induction of protein expression 
was performed with IPTG at a final concentration of 0.2 mM at 24 °C for overnight. The 
cell pellet was resuspended in lysis buffer containing 50 mM Tris, 100 mM KCl, 2 M urea 
and one tablet of Pierce protease and phosphatase inhibitor mini tablets, EDTA-free 




at 9000 x g for 5 min at 4 °C, and the pellet was collected. After four lysis washes, the 
pellet was resuspended in solubilization buffer containing 50 mM Tris, 100 mM KCl, 8 M 
guanidine, and 10 mM β-mercaptoethanol at pH 8.5. The solution was incubated at 4°C 
overnight and then centrifuged at 9000 x g for 15 min at 4 °C. The supernatant was then 
purified with TALON cobalt resin (Clontech, Mountain View, CA) and diluted into refolding 
buffer (50 mM Tris, 500 mM NaCl, 400 mM sucrose, 3 mM reduced glutathione, 0.3 mM 
oxidized glutathione, 0.5% Triton X-100, 10% glycerol, and 10 mM imidazole at pH 8.5). 
The solution was stirred at 200 rpm at 4 °C for 24 h and then purified with TALON cobalt 
beads (Clontech, Mountain View, CA) by immobilized metal affinity chromatography 
(IMAC). After incubation of the supernatant with cobalt resin for 1 h at 4 oC, an imidazole 
gradient method was used to collect protein at elution buffer containing 13 mM sodium 
phosphate monobasic, anhydrous, 73 mM sodium phosphate dibasic, anhydrous, 300 
mM NaCl, 8 M urea and 10 mM imidazole at pH 7.4. The protein in elution buffer was 
then diluted by 1:10 into refolding buffer containing 50 mM Tris, 500 mM NaCl, 400 mM 
sucrose, 3 mM reduced glutathione, 0.3 mM oxidized glutathione, 0.5 % Triton X-100, 10% 
glycerol, and 10 mM imidazole at pH 8.5. The solution was stirred at 250 rpm at 4 oC for 
48 hours. After 48 hours in refolding buffer, the protein was dialyzed against 1x PBS with 
10% glycerol (pH 7.4) using SnakeSkin™ Dialysis Tubing, 10 K MWCO, 35 mm 
(ThermoFisher Scientific, Waltham, MA). Finally, the protein was concentrated in 
Amicon® ultra protein concentrator, 10 kDa, 15 ml (EMD Millipore Corporation, Danvers, 
MA). Protein expression for CXCR4-1P, CXCR4_2P was performed as described above 





Periplasmic extraction method 
The protein was induced as previously described in the inclusion body method. 
Cell pellets were collected by centrifugation at 9000 rpm for 10 minutes at 4 ºC. For 1L 
of culture, resuspending cell pellet with 25ml of ice-cold buffer A (50 mM Tris-HCl, 1mM 
EDTA, 20% sucrose, protease inhibitor tablet, at pH 7.2). The resuspension was 
incubated on ice for 30min~1hr with gentle shaking, and then was centrifuged at 10,000 
xg for 20min. The supernatant was collected. Then, resuspending cell pellet with 25ml 
of buffer B (cold 5 mM MgSO4 with protease inhibitor), also incubate for 30min on ice. 
After centrifuging at 10,000 xg for 20 minutes, retain the 2nd supernatant and combined 
it with 1st supernatant. The protein-containing supernatant was then dialyzed against 1x 
PBS with 10% glycerol to remove EDTA. The dialyzed solution was then purified by 
cobalt-bead-based IMAC chromatography as previously described.  
Purification and identification  
Protein samples were mixed with 4x Laemmli SDS sample reducing buffer (Alfa 
Aesar, Haverhill, MA) and then denatured at 95 oC for 10 minutes. After denaturation, 
protein samples and PageRulerTM plus prestained protein ladder (Thermofisher Scientific, 
Waltham, MA) were loaded into 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). The SDS-PAGE was run at 180 V for 1.5 h and then 
stained with Coomassie Brilliant Blue R-250 staining solution (Bio-Rad, Hercules, CA) for 
1 h. After staining, the SDS-PAGE was destained by the destain solution containing 50% 
of methanol, 40% distilled water, and 10% glacial acetic acid overnight. The next day, the 
SDS-PAGE was further destained by distilled water in a rocker for 30 minutes and then 




stained with ethidium bromide following electrophoresis on 1% agarose gel to detect 
nucleic acid contaminants.  
RNA Complexation Assay 
The Quant-iTTM Ribogreen®RNA Assay kit purchased from ThermoFisher 
Scientific (Waltham, MA) was used to assay RNA complexation. A fixed amount, 20ng of 
22-bp miRNA duplex mimic was complexed with the following molar ratios of each protein: 
1:0, 1:10, 1:20, 1:30, 1:40, and 1:50 at room temperature for 30 minutes. And then, 100 
ul of Quant-iTTM Ribogreen reagent solution (1:200 dilution) was added to each well in a 
Corning® 96 well black polystyrene microplate (Sigma-Aldrich, St.Louis, MO). After 
incubation at room temperature for 5 minutes in the dark, fluorescence was measured at 
an excitation wavelength of 480 nm and an emission wavelength of 520 nm by using a 
SpectraMax i3 Plate Reader. 
Anion exchange column  
The pH of the protein samples was increased to 12, so that the pH is greater 
than the isoelectric point of the CXCR4-1P (isoelectric point =9.7). At such alkalized 
conditions, fusion proteins are no longer positively charged, leading to the dissociation 
of nucleic acid contaminants. The protein sample was then loaded onto columns packed 
with POROS AEX resins (Thermo scientific) and incubated for 30 min. Packing of 
columns was performed according to specifications by the manufacturer. The more 
negatively charged nucleic acids would bind to resin more tightly than the CXCR4-1P 
fusion proteins. Buffers containing increased NaCl concentrations were used as 




low concentration buffer, whereas the contaminants were eluted with a high 
concentration buffer.  
High-salt-wash assisted IMAC purification 
After proteins were applied to a His-trap cobalt bead packed column, the 
flowthrough was discarded by gravity flow. The beads were then incubated with 1.5 M 
NaCl buffer for 20 minutes. For a 1 ml of bead slurry, 50 ml buffer was used. The 
concentration of NaCl was then brought down to 200mM by sequential gradient washes. 
The protein of interest was then eluted using elution buffer (50 mM sodium phosphate, 
200 mM sodium chloride, 250mM imidazole, pH 7.4).  
ELISA-based fusion protein binding affinity assay 
The binding affinity of the CXCR4 scFv and CXCR4_1P was assessed with an 
ELISA. The 96-well plate was first coated with neutravidin and then coated with the 
biotinylated CXCR4 N-terminal peptide. The purified fusion proteins were serially diluted 
and added to the 96-well plate.  Anti-FLAG-HRP conjugate (Sigma Aldrich) was added 
to bind fusion proteins as the primary antibody. 100 µL of Ultra-TMB substrate (Thermo 
Fisher Scientific) was added to quantify the amount of bound fusion proteins. The 
reaction was then quenched with 12.5 M H2SO4 aqueous solution. Readings were taken 
using a plate reader with the wavelength set to 450 nm. 
Luciferase knockdown assay 
MDA-MB-231 breast cancer cells stably expressing firefly luciferase were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-




in 96-well plates at a density of 10,000/well. CXCR4-1P fusion proteins were complexed 
with 0.14 pmol of either anti-luciferase siRNA or non-specific siRNA at 1:10 1:20, 1:40, 
and 1:50 (protein to siRNA) molar ratios. The CXCR4_RBM/siRNA nanoplexes or 
lipofectamine/siRNA formulation were added to each well containing 200 μl of medium 
supplemented with 10% FBS. After 24 h incubation, the medium was replaced, and the 
cells were allowed to grow for an additional 24 h. Non-specific siRNA was used as a 
negative control to account for cytotoxic effects or off-target effects. On day 3, cells were 
washed with PBS and 100 μl of Brightglo reagent (Promega) was added to each well and 
incubated for 15 min. Luciferase expression was measured with the plate reader. 
Luciferase expression was expressed as a percentage of naked siRNA treated cells. All 
experiments were performed in triplicate and are presented as mean ± sd. 
Molecular docking 
The structure of protamine peptides was predicted by the I-TASSER server using 
iterative template-based fragment assembly simulations. The structure of miRNA duplex 
was predicted by SimRNA web server, which utilizes the Monte Carlo method to sample 
the conformational space, and relies on a statistical potential to describe the folding 
interaction. Docking simulations were performed using the HDOCK server, in which an 
improved shape-based pairwise scoring function has been used (available 
at http://hdock.phys.hust.edu.cn/). The docking server uses both sequences and 
structures as input for proteins, and uses structure input for DNAs/RNAs. The binding 





Results and discussion 
Cloning of alternative CXCR4_RBM protein constructs 
Our CXCR4-RBM fusion proteins were constructed based on a CXCR4-targeting 
scFv that we identified using phage display. In previously published data, we illustrated 
that the CXCR4-scFv bind to both human and mouse CXCR4+ cells with high affinity 10. 
The short protamine sequence was fused to the C terminus of CXCR4_scFv protein.  
We first started with inclusion body isolation for our protein expression and then 
observed significant nucleic acid contaminants. In order to solve this problem, we 
implemented another isolation method: periplasmic extraction. This method requires a 
signaling peptide to allow bacteria to export proteins into periplasmic space. In general, 
signaling sequences are rich in hydrophobic amino acids, such as alanine, valine, and 
leucine, which is an essential feature for the secretion of the proteins into the periplasm 
of E. coli 12. Several studies have used ompA (MKKTAIAIAVALAGFATVAQA) as the 
signaling peptide for their scFv proteins and showed successful isolation of functional 
proteins from the periplasm 13,14.  
Therefore, we incorporated the ompA peptide sequence at the N terminus of the 
CXCR4-scFv, and the new ompA_CXCR4-scFv DNA fragment was cloned into the 
pET21a vector (Novagen, Burlington, MA). Sequential cloning was performed for 
ompA_CXCR4_2P. The schematic of cloning is shown in Figure 1.  
The images of EtBr-stained 0.8% agarose gel of CXCR4 were selected as 
representative images to illustrate the cloning process shown in Figure 2. The two images 




fragments. After ligation and transformations, multiple colonies were picked for test 
digestion. The agarose gel image of the digested CXCR4-2P was selected as the 
representative image for an illustration, as shown in Figure 3. The molecular length of 
one protamine insert was about 85 bp, and the size of two protamine inserts would be 
170 bp. In Figure 3, the released fragments (red boxed) were the two-protamine inserts, 
indicating potentially working candidates of plasmids. The plasmid sequencing was 
performed for further confirmation of correct cloning. The alignment of sequencing results 












Protein expression and purification 
Plasmids encoding for CXCR4, CXCR4_1P, CXCR4_2P were transformed into a 
BL21 strain for protein expression. CXCR4 (MW = 32 kDa), CXCR4_1P (MW = 35 kDa), 
CXCR4_2P (MW = 38kDa) were isolated from E. coli bacterial culture using either 
inclusion body isolation method (Fig. 5A) or periplasmic extraction (SDS-PAGE images 
are not shown). Because the CXCR4 fusion protein construct contains 6x His tag, the 
protein of interest can be purified using an immobilized metal affinity column. The single 
band at the correct molecular weight position on the SDS-PAGE image indicated the 
successful isolation of the protein of interest. The fusion proteins with one or two RBMs 
(CXCR4_1P, and CXCR4_2P) displayed a slightly higher shift in migration due to an 






Comparison of two isolation methods 
When bacteria cells are expressing proteins, produced proteins can bind to 
bacteria cellular nucleic acids, impairing the complexation efficiency to therapeutic 
miRNAs or siRNAs. Besides the bound nucleic acids, free cellular nucleic acids will also 
be released if the isolation method requires cell lysis (e.g., inclusion body isolation). As 
shown in Figure 6B, proteins isolated using the inclusion body method showed substantial 
nucleic acid contamination on the agarose gel. When complexing the proteins to the 
miRNA, the RiboGreen assay showed an increase in fluorescent signal, which mainly 
comes from the free nucleic acid contamination present in the protein sample, as shown 
in Figure 6A. On the other hand, when proteins were isolated from the periplasmic space, 
they ended up with much fewer contaminants. Periplasmic extraction has several 
advantages over inclusion body isolation, such as less protease activity and the 
production of more stable and correctly folded proteins 15. However, periplasmic extracted 




body. For a liter of culture media, the inclusion body could generate about 200~500 ug of 
fusion proteins, whereas periplasmic extraction only generates roughly about 30 ugs. 
Moreover, this isolation method did not completely resolve the contamination issue. As 
shown in Figures 6C and 6D, the agarose gel image and RiboGreen assay illustrated that 
there are nucleic acid contaminants in proteins that are periplasmically extracted. The 
fluorescent signal magnitudes in Figures 6A and 6C were different because they were 
measured on two different plate readers, so a direct comparison is not possible in this 
case. However,  when comparing Figures 6B and 6D, it is clear that periplasmic extraction 
resulted in much fewer nucleic acid contaminants in the eluted protein sample. 
The association of CXCR4_RBM proteins with the contaminating bacterial 
nucleic acid would significantly limit the binding of therapeutic small RNAs. Therefore, to 
recover functional RNA-binding CXCR4_RBM proteins, not only do we need to remove 
the free nucleic acids, but also dissociate the bound nucleic acids from the protein. 







Anion exchange column  
We first assessed if the nucleic acid contaminants can be removed from the 
CXCR4_1P using anion exchange purification. By increasing the pH to 12, the bound 
nucleic acids are expected to dissociate from the protein, because due to its isoelectric 
point of 9.7, the proteins are no longer positively charged at high pH. The more 
negatively charged nucleic acids bound to the resin more tightly than the CXCR4-1P 
fusion proteins, and thus the protein eluted at lower concentration buffer, whereas the 
contaminants eluted at high concentration buffer (1M NaCl) shown in Figure 7. Based 
on the RiboGreen assay result (Figure 8), CXCR4-1P without anion-exchange treatment 
had an increased fluorescent signal (red line), indicating the original protein has nucleic 
acid contamination. While the CXCR4-1P was treated with the anion-exchange column, 
it (blue line) showed a certain level of complexation with miRNA duplex, but the 







High-salt-wash assisted IMAC purification 
It is well known that protein-RNA interactions are largely electrostatic in nature 
and thus are sensitive to high salt concentrations. Since the dissociation of nucleic acids 
from proteins is dependent on salt concentration, high salt (1.5M NaCl) with extensive 
washing steps during affinity purification could theoretically remove the dissociated 
contaminants from the protein. After capturing the protein of interest by cobalt beads, 
the beads were then incubated with 1.5 M NaCl buffer to mediate nucleic acid 
dissociation. At such a high salt concentration, the ions will weaken the binding between 
the fusion protein and the impurity by interrupting the electrostatic interactions. The 
dissociated nucleic acids were washed off the column, leaving pure protein bound to 
cobalt beads, which were then eluted. From the agarose gel image (Fig 9), we can 
clearly see that nucleic acid contaminants were removed successfully by the high-salt 





After complexing these proteins with 20 ng miRNA, the RiboGreen assay (Fig. 
10) showed that CXCR4_1P complexed about 50% of miRNA at as low as 1:10 pmol 
molar ratio (protein to miRNA), and then gradually plateaued out. The maximum 
complexation efficiency is about 55%, which was an improvement compared to all 
previous approaches. However, the maximum complexation efficiency is still not 100%. 
One possible explanation would be that the complexation between CXCR4_1P and 
miRNA was not sufficiently tight, and the RiboGreen dye molecule was still able to 
diffuse into the complex, intercalate with the RNA, and generate a fluorescent signal16. 
Therefore, there is a need to further improve the RNA binding/loading efficiency. The 
different CXCR4_RBM constructs were designed to characterize the length of RBM 
regarding its ability to complex and functionally deliver small RNAs. To figure out the 
maximum complexation, a single-stranded miRNA could be incorporated as a better 




fluorescence signal generated from this control group could be considered as the 
theoretical maximum. 
 
ELISA-based binding assay 
To confirm that the purified proteins are still able to bind and target the CXCR4 
receptor, an ELISA-based binding assay was performed. In Figure 11, the ELISA result 
showed successful binding of CXCR4-1P fusion proteins to the N-terminus of the 
CXCR4 receptor, with a KD value of 104 ± 61 nM. The CXCR4-scFv without RBM is also 






To assess if the CXCR4_1P can deliver siRNA into cells, we performed a 
luciferase gene silencing assay. Luciferase-expressing MDA-MB-231 cells were treated 
with either CXCR4/siRNA or CXCR4-1P/siRNA complexes with different protein to 
siRNA molar ratios. The non-specific siRNA duplex (NS_siRNA) was complexed with 
fusion proteins as a negative control to account for cytotoxicity or off-target effects. A 
fixed amount of siRNA, 20 ng (0.14 pmol) was used in all experiments, and all the data 
were expressed as a percentage of control (naked siRNA treated cells). Based on 
Figure 12A, when cells were treated with CXCR4/siRNA complexes, the luminescence 
was not significantly affected. When cells were treated with CXCR4_1P/anti-Luc siRNA, 
the gene was knocked down about 10%~15% starting at 1:20 (protein:siRNA) molar 
ratio, indicating successful cellular delivery of siRNA (Fig. 12B). At 1:50 (protein:siRNA) 
molar ratio, the luminescence was decreased compared to the control group.  The 




2) low CXCR4_1P complexation efficiency, or 3) insufficient endosomal escape. Further 
experiments are needed to find the optimal dosage of siRNA to achieve an adequate 
luciferase knockdown with minor or no cytotoxicity, and also additional optimization of 
the RBM is needed. Another possible reason could be the endosomal entrapment, 
which not only prevents siRNA from reaching the cytosol but also degrades siRNA. 
Strategies aimed to overcome this issue includes lipid conjugation, fusogenic peptides, 
and chemical agents (e.g. chloroquine)17,18. One study conducted by Wickline et.al, has 
demonstrated that a melittin-based strategy could disrupt the membrane and enable 
safe and effective endosomolysis19.  For future studies, we could incorporate 
endosomal escape agents, such as melittin, to enhance the endosomal escape of the 
CXCR4_siRNA complexes. 
 
Computational molecular docking of RBM/miRNA_Duplex complexes 
The CXCR4-1P contains a single short fragment of the RNA-binding element of 
the protamine (RSQSRSRYYRQRQRSRRRRRRS). The single protamine peptide is 
only 7 nm in length if we assume it adopts an alpha-helix confirmation, while the overall 




we can visually observe the size difference between the small RNA duplex and the 
protamine sequences. Figure 13 shows that one protamine sequence only binds the 
RNA duplex partially, while the 3-protamine sequence displays more contacts with the 
RNA duplex. One study conducted by Dr. Jordina Guillén-Boixet showed that the extent 
of protein/RNA condensation could be controlled by the valence of arginine residues in 
the RNA-binding regions. His study concluded that the higher the number of arginine 
residues, the better the complexation of the RNA 20. The longer RBM with higher charge 
density may improve protein/RNA complexation and thus provide more protection from 
degradation.    
Due to the complexity of molecular docking methodologies and algorithms, the 
following docking was simulated in an extreme case, where only one molecule of 
protamine was complexed with one molecule of miRNA duplex. The simulation only 
illustrated the protamine peptide, but not CXCR4_RBM fusion proteins. With additional 
CXCR4-scFv fused with the protamine, the acutual contacting region would be 
alternated. The molecular docking was only aimed to visualize the length difference, 
further advanced simulation is needed for a more accurate prediction of the binding 






CXCR4-RBM fusion proteins that are overexpressed in E. coli tend to bind 
endogenous RNAs with high affinity due to their RNA-binding domain (e.g., protamine 
sequence) featuring a positively charged stretch of arginines. Nucleic acid 
contaminations are an inherent problem shared among most RNA-binding and 
positively charged protein purification8,21. The contaminating nucleic acids occupied the 
RNA-binding domain, which limited binding and complexation between therapeutic RNA 
and the fusion proteins. Different isolation methods could improve the nucleic acid 
contaminants. Unlike inclusion body isolation, the periplasmic extraction could prevent 
most endogenous nucleic acids released from the bacterial cell. However, the low 
protein yield became another limiting step for downstream experiments.  
Studies have reported a variety of nucleic-acid removal approaches such as 
ethanol precipitation from crude cell extracts 22,23, heparin-sepharose affinity 
chromatography 24, precipitation with the polycation PEI 21, and so on. In this study, we 
tested several nucleic acid removal methods, such as the anion exchange column. PEI 
precipitation, and others (see in Appendix). The anion exchange method could remove 
partially bound nucleic acids but failed to economically produce large amounts of 
functional proteins required for structural and other biophysical studies. The extreme pH 
conditions, additional incubation time, and washing steps may denature the protein, 
making this method unpredictable and unreliable without further structure-specific 
characterization. 
As an alternative route, high-salt washes were implemented during the IMAC 




(isoelectric point = 9.71) and nucleic acids are fully ionized. Because the electrostatic 
interactions contribute to the stability of protein/nucleic acid complexes, by adding 
additional salt, we neutralized the electrostatic interactions and thus dissociated nucleic 
acids from the proteins. As a result, the high-salt wash method successfully improved 
the removal of most bound nucleic acids from the protein, leaving relatively pure 
functional RNA-binding CXCR4 fusion proteins. 
The purified fusion proteins retained their shape and ability to bind the specific 
receptor. They have been shown to deliver siRNA successfully as well, albeit efficiency 
was low. Future studies will be focusing on structural optimization of the RBMs for 
enhanced small RNA delivery. Possible strategies include increasing RBM length, the 
position of charged amino acids, and incorporating aromatic amino acids, such as 
tyrosine, that can effectively mediate the π-π interactions with the RNA backbone and 
enhanced nucleic acid/RBM interactions. Additionally, there may be a need to 
incorporate endosomal escape agents, such as melittin, into the scFv-RBM fusion 
proteins for enhanced gene silencing. These studies could provide a framework for the 










APPENDIX: UNSUCCESSFUL BACTERIAL-CONTAMINATION-REMOVAL 
APPROACHES 
 
I. Polyethyleneimine (PEI) precipitation  
The protein was isolated following the inclusion body isolation. After eluting 
proteins from the IMAC column, the fractions containing the protein of interest were 
collected, pooled, and the ionic strength of the solution was increased to 1 M sodium 
chloride. PEI was added to the final concentration of 0.5~0.8% (w/v) and the solution 
was incubated for 1 h. The resulting suspension was centrifuged at 15000g for 20 min to 
remove PEI-nucleic acid complexes. The protein was recovered from the excess of PEI 
present in the supernatant by precipitation with 75% ammonium sulfate. After overnight 
incubation, this suspension was centrifuged, and the pellet containing the protein was 
resuspended in binding buffer (50 mM sodium phosphate, pH 7.4, 200 mM sodium 
chloride, 1 mM DTT, 0.02% sodium azide), applied onto a cobalt-beads-packed column, 
and purified with the elution buffer. Protein samples were concentrated using an Amicon 
Ultra-15 (Millipore) with a 10 kDa MWCO membrane. Residual traces of imidazole were 
removed by dialyzing the eluate at 4 °C against PBS buffer containing 10% glycerol. 
Protein isolated using this purification method was then complexed with the 
miRNA duplex for RiboGreen assay. Comparing to the increased curve shown in Figure 
6A, the flat curve of CXCR4_1P in Figure 14 indicated a successful removal of free 
unbound nucleic acids in the protein sample. However, the PEI precipitation method 
was not able to remove the bound contaminants from the protein, leaving the 
CXCR4_1P with no complexation activity. Another problem of the PEI precipitation 




RNA complexation, and thus interfering with the downstream miRNA complexation 
assay. 
 
II. Nuclease enzyme treatment  
Following the inclusion body isolation method, the bacteria cell pellet was 
resuspended in lysis buffer containing 25 units/ml benzonase nuclease (EMD Millipore). 
Comparing to the bacterial cell suspension in normal lysis buffer, with additional 
benzonase nuclease, the viscosity was significantly reduced, indicating successful 
digestion of free nucleic acids contaminants. However, the eluted proteins still contain 
nucleic acid contaminants, shown in Figure 15. One explanation could be that the 
nuclease was unable to digest the bound nucleic acids because they were shielded or 
protected by the proteins. Additional pre-treatment is required to dissociate the bound 
nucleic acid before enzyme digestion. More importantly, this method requires successful 
removal of nuclease enzyme, which could digest miRNA of interest in the downstream 
assays. An alternative approach would be implementing an immobilized nuclease-
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